Details

Treatment of benign prostatic hyperplasia by natural drugs
ID Csikós, Eszter (Author), ID Sollner Dolenc, Marija (Author), ID Kenda, Maša (Author), ID Kočevar Glavač, Nina (Author), ID Farkas, Ágnes (Author), et al.

.pdfPDF - Presentation file, Download (561,97 KB)
MD5: 15770863F1F4C399C9B5072BAAACDB5F
URLURL - Source URL, Visit https://www.mdpi.com/1420-3049/26/23/7141 This link opens in a new window

Abstract
Benign prostatic hyperplasia (BPH) is one of the most common urinary diseases affecting men, generally after the age of 50. The prevalence of this multifactorial disease increases with age. With aging, the plasma level of testosterone decreases, as well as the testosterone/estrogen ratio, resulting in increased estrogen activity, which may facilitate the hyperplasia of the prostate cells. Another theory focuses on dihydrotestosterone (DHT) and the activity of the enzyme 5α-reductase, which converts testosterone to DHT. In older men, the activity of this enzyme increases, leading to a decreased testosterone/DHT ratio. DHT may promote prostate cell growth, resulting in hyperplasia. Some medicinal plants and their compounds act by modulating this enzyme, and have the abovementioned targets. This review focuses on herbal drugs that are most widely used in the treatment of BPH, including pumpkin seed, willow herb, tomato, maritime pine bark, Pygeum africanum bark, rye pollen, saw palmetto fruit, and nettle root, highlighting the latest results of preclinical and clinical studies, as well as safety issues. In addition, the pharmaceutical care and other therapeutic options of BPH, including pharmacotherapy and surgical options, are discussed, summarizing and comparing the advantages and disadvantages of each therapy.

Language:English
Keywords:benign prostatic hyperplasia, medicinal plants, phytotherapy, saw palmetto, preclinical studies, clinical efficacy, safety issues
Work type:Article
Typology:1.02 - Review Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2021
Number of pages:32 str.
Numbering:Vol. 26, iss. 23, art. 7141
PID:20.500.12556/RUL-136713 This link opens in a new window
UDC:616.65-007.61
ISSN on article:1420-3049
DOI:10.3390/molecules26237141 This link opens in a new window
COBISS.SI-ID:86644739 This link opens in a new window
Publication date in RUL:17.05.2022
Views:1060
Downloads:202
Metadata:XML DC-XML DC-RDF
:
CSIKÓS, Eszter, SOLLNER DOLENC, Marija, KENDA, Maša, KOČEVAR GLAVAČ, Nina and FARKAS, Ágnes, 2021, Treatment of benign prostatic hyperplasia by natural drugs. Molecules [online]. 2021. Vol. 26, no. 23,  7141. [Accessed 1 April 2025]. DOI 10.3390/molecules26237141. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=136713
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Molecules
Shortened title:Molecules
Publisher:MDPI
ISSN:1420-3049
COBISS.SI-ID:18462981 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:01.12.2021

Secondary language

Language:Slovenian
Keywords:predklinične študije, klinična učinkovitost, varnostne težave

Projects

Funder:EC - European Commission
Funding programme:Erasmus+, Key Action 2: Strategic Partnerships
Project number:2020-1-CZ01-KA203-078218
Name:Open Access Educational Materials on Naturally Occurring Molecules

Similar documents

Similar works from RUL:
  1. ǂThe ǂclinical significance of determining the concentration of free fatty acid binding protein as an early marker of acute myocardial infarction
  2. Diagnostic value of alpha fetoprotein receptor in discrimination prostate cancer
  3. Clinical value of precursor prostate specific antigen in patients with low plasma concentration of prostate specific antigen
  4. Klinični pomen določanja koncentracije metabolitov adrenalina in noradrenalina v plazmi pri bolnikih z nevroblastomom (SLO)
  5. Effect of selected single nucleotide polymorphisms on the concentrations of tumor markers in patients with prostate cancer
Similar works from other Slovenian collections:
  1. Benigna hiperplazija prostate (BHP)
  2. Nadzorovano opazovanje (watchful waiting) kot možna oblika zdravljenja lokaliziranega raka prostate
  3. Prostatični specifični antigen
  4. Zdravstvena nega bolnika z rakom prostate na sistemskem zdravljenju
  5. Zdravstvena nega bolnika z rakom prostate na sistemskem zdravljenju

Back